Advertisement

Herz

pp 1–6 | Cite as

Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients

  • Irfan Veysel DuzenEmail author
  • Elif Oguz
  • Yusuf Cekici
  • Fethi Yavuz
  • Ertan Vuruskan
  • Isa Sincer
  • Fatih Poyraz
  • Hayri Alıcı
  • Umit Yuksek
  • Abdullah Orhan Demirtas
  • Murat Sucu
Original articles

Abstract

New-generation oral anticoagulants (NOACs) are now preferred as a first-line treatment in the management of atrial fibrillation for prevention of thromboembolic complications. Mean platelet volume (MPV), one of the indicators of increased platelet activity, is also associated with an increased stroke risk in atrial fibrillation patients. The aim of this study was to evaluate changes in MPV, platelet distribution width (PDW) and plateletcrit following use of NOACs. The study included 116 patients with non-valvular atrial fibrillation without previous NOAC use. Complete blood counts, biochemical analyses and echocardiography were performed for all patients. No significant differences were observed in MPV or other platelet indices at 6 months compared to baseline. Our results indicate that MPV and other platelet indices are not affected by NOAC use in non-valvular atrial fibrillation patients.

Keywords

Arrhythmias Stroke Risk factors Echocardiography INR 

Wirkung neuer oraler Antikoagulanzien auf Thrombozytenparameter bei Patienten mit nichtvalvulärem Vorhofflimmern

Zusammenfassung

Neue orale Antikoagulanzien (NOAC) werden mittlerweile für die Erstlinientherapie bei Vorhofflimmern zur Prävention thromboembolischer Komplikationen bevorzugt eingesetzt. Das mittlere Thrombozytenvolumen („mean platelet volume“ [MPV]), ein Indikator der erhöhten Thrombozytenaktivität, ist auch mit einem erhöhten Schlaganfallrisiko bei Patienten mit Vorhofflimmern assoziiert. Ziel der vorliegenden Studie war es, Veränderungen im MPV, der Thrombozytenverteilungsbreite und dem Thrombokrit nach Einsatz von NOAC zu untersuchen. Eingeschlossen wurden 116 Patienten mit nichtvalvulärem Vorhofflimmern ohne vorherige NOAC-Einnahme. Bei allen Patienten wurden große Blutbilder erstellt, zudem wurden biochemische Analysen und eine Echokardiographie durchgeführt. Im Vergleich zur Ausgangsmessung fanden sich nach 6 Monaten keine signifikanten Unterschiede im MPV oder in anderen Thrombozytenparametern. Unsere Ergebnisse zeigen, dass das MPV und andere Thrombozytenparameter bei Patienten mit nichtvalvulärem Vorhofflimmern nicht durch eine NOAC-Einnahme beeinträchtigt sind.

Schlüsselwörter

Herzrhythmusstörungen Schlaganfall Risikofaktoren Echokardiographie INR 

Notes

Compliance with ethical guidelines

Conflict of interest

I.V. Duzen, E. Oguz, Y. Cekici, F. Yavuz, E. Vuruskan, I. Sincer, F. Poyraz, H. Alıcı, U. Yuksek, A.O. Demirtas and M. Sucu declare that they have no competing interests.

All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A (2016) The epidemiology of atrial fibrillation and stroke. Cardiol Clin 34(2):255–268Google Scholar
  2. 2.
    Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT et al (2015) 7.50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study a cohort stud. Lancet 386(9989):154–162Google Scholar
  3. 3.
    Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988Google Scholar
  4. 4.
    Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH (2019) Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. J Am Coll Cardiol 73(5):612–619Google Scholar
  5. 5.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962Google Scholar
  6. 6.
    Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ (2013) Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 1(1):21–28Google Scholar
  7. 7.
    Camm AJ, Breithardt G, Crijns H, Dorian P, Kowey P, Le Heuzey JY, Merioua I, Pedrazzini L, Prystowsky EN, Schwartz PJ et al (2011) Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 58(5):493–501Google Scholar
  8. 8.
    Wagner DD, Burger PC (2003) Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23(12):2131–2137Google Scholar
  9. 9.
    Fateh-Moghadam S, Htun P, Tomandl B, Sander D, Stellos K, Geisler T, Langer H, Walton K, Handschu R, Garlichs C et al (2007) Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 97(6):974–978Google Scholar
  10. 10.
    Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7(2):157–161Google Scholar
  11. 11.
    Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS, Hong SP et al (2013) Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 24(5):401–406Google Scholar
  12. 12.
    Tekin G, Tekin YK, Sivri N, Yetkin E (2013) Mean platelet volume in patients with nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis 24(5):537–539Google Scholar
  13. 13.
    Shilpi K, Potekar RM (2018) A study of platelet indices in type 2 diabetes mellitus patients. Indian J Hematol Blood Transfus 34(1):115–120Google Scholar
  14. 14.
    Gang L, Yanyan Z, Zhongwei Z, Juan D (2017) Association between mean platelet volume and hypertension incidence. Hypertens Res 40(8):779–784Google Scholar
  15. 15.
    Icli A, Aksoy F, Nar G, Kaymaz H, Alpay MF, Nar R, Guclu A, Arslan A, Dogan A (2016) Increased mean platelet volume in familial cypercholesterolemia. Angiology 67(2):146–150Google Scholar
  16. 16.
    Nadar S, Blann AD, Lip GY (2004) Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 36(7):552–557Google Scholar
  17. 17.
    Erhart S, Beer JH, Reinhart WH (1999) Influence of aspirin on platelet count and volume in humans. Acta Haematol 101(3):140–144Google Scholar
  18. 18.
    Gu X, Fu X, Wang Y, Zhang W, Fan W, Jiang Y, Hao G, Miao Q, Li Y, Zhi W (2017) Comparison of ticagrelor and high-dose clopidogrel on the platelet functions in patients with inadequate response to clopidogrel. Am J Cardiovasc Dis 7(1):1–8 (eCollection 2017)Google Scholar
  19. 19.
    Jagroop IA, Mikhailidis DP (2000) Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 14(9):581–585Google Scholar
  20. 20.
    Bath P, Algert C, Chapman N, Neal B (2004) PROGRESS Collaborative Group Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35(3):622–626Google Scholar
  21. 21.
    Gungoren F, Besli F, Caliskan S, Polat U, Basar C, Serdar OA (2016) Statin therapy may not effect NLR and MPV levels in patients with hypercholesterolemia: a retrospective study. Angiology 67(6):536–540Google Scholar
  22. 22.
    Akyüz A, Akkoyun DÇ, Değirmenci H, Oran M (2016) Rosuvastatin decreases mean platelet volume in patients with diabetes mellitus. Angiology 67(2):116–120Google Scholar
  23. 23.
    Arık OZ, Ozkan B, Kutlu R, Karal H, Sahin DY, Kaypaklı O, Ozel D, Cayli M (2014) Relationship between platelet indices and international normalized ratio in patients with non-valvular atrial fibrillation. Platelets 25(5):311–316Google Scholar
  24. 24.
    Pizzulli L, Yang A, Martin JF, Lüderitz B (1998) Changes in platelet size and count in unstable angina compared to stable angina or non-cardiacchest pain. Eur Heart J 19(1):80–84Google Scholar
  25. 25.
    Lai HM, Xu R, Yang YN, Ma YT, Li XM, Zhao Q, Chen QJ, Zhai H, Liu F, Chen BD (2015) Association of mean platelet volume with angiographic thrombus burden and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Catheter Cardiovasc Interv 85(Suppl 1):724–733Google Scholar
  26. 26.
    Taglieri N, Saia F, Rapezzi C, Marrozzini C, Bacchi Reggiani ML, Palmerini T, Ortolani P, Melandri G, Rosmini S, Cinti L et al (2011) Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. Thromb Haemost 106(1):132–140Google Scholar
  27. 27.
    Higaki T, Kurisu S, Watanabe N, Ikenaga H, Shimonaga T, Iwasaki T, Mitsuba N, Ishibashi K, Dohi Y, Fukuda Y et al (2016) Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease   undergoing percutaneous coronary intervention. Heart Vessels 31(3):269–274Google Scholar
  28. 28.
    Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G (2015) Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Expert Opin Pharmacother 16(12):1739–1747Google Scholar
  29. 29.
    Yang A, Pizzulli L, Lüderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117(4):371–377Google Scholar
  30. 30.
    Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, Demircan S, Sezgin A, Ozin B, Muderrisoglu H (2008) Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis 19(5):411–414 (Jul)Google Scholar
  31. 31.
    Bayar N, Arslan S, Cagirci G, Ureyen CM, Cay S, Yuksel IO, Koklu E, Erkal Z, Kucukseymen S (2015) Usefulness of mean platelet volume for predicting stroke risk in paroxysmal atrial fibrillation patients. Blood Coagul Fibrinolysis 26(6):669–672Google Scholar
  32. 32.
    Ha SI, Choi DH, Ki YJ, Yang JS, Park G, Chung JW, Koh YY, Chang KS, Hong SP (2011) Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 22(6):408–414Google Scholar
  33. 33.
    Choi SW, Kim BB, Choi DH (2017) Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation. Clin Cardiol 40(11):1013–1019Google Scholar
  34. 34.
    Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS, Hong SP (2013) Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 24(5):401–406Google Scholar
  35. 35.
    Wan JL, Ma ZW (2017) Value of Mean Platelet Volume for Prognosis of Patients with Acute Cerebral Infarction. Clin Lab 63(11):1801–1807Google Scholar
  36. 36.
    Gul SS, Gozke E (2018) Mean platelet volume in patients with acute ischemic stroke with nonvalvular atrial fibrillation. Clin Lab.  https://doi.org/10.7754/clin.lab.2018.180543 Google Scholar
  37. 37.
    Yılmaz F, Köklü E, Kizilirmak Yilmaz F, Sarıönder Gencer E, Alparslan AŞ, Yıldırımtürk Ö (2017) Evaluation of mean platelet volume and platelet distribution width in patients with asymptomaticintermediate carotid artery plaque. Kardiol Pol 75(1):35–41Google Scholar
  38. 38.
    Providência R, Faustino A, Paiva L, Fernandes A, Barra S, Pimenta J, Trigo J, Botelho A, Leitão-Marques AM (2013) Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 13:40Google Scholar
  39. 39.
    Choudhury A, Chung I, Blann AD, Lip GY (2007) Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of “healthy control subjects” and “disease control subjects” in sinus rhythm. J Am Coll Cardiol 49(19):1957Google Scholar
  40. 40.
    Thompson CB, Love DG, Quinn PG, Valeri CR (1983) Platelet size does not correlate with platelet age. Blood 62(2):487–494Google Scholar
  41. 41.
    Pathansali R, Smith N, Bath P (2001) Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 12(5):292–297Google Scholar
  42. 42.
    Gladwin AM, Martin JF (1990) The control of megakaryocyte ploidy and platelet production: biology and pathology. Int J Cell Cloning 8(4):291–298Google Scholar
  43. 43.
    Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I (2010) Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 14(1):28–32Google Scholar
  44. 44.
    Khandekar MM, Khurana AS, Deshmukh SD, Kakrani AL, Katdare AD, Inamdar AK (2006) Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 59(2):146–149Google Scholar
  45. 45.
    Mohr R, Martinowitz U, Golan M, Ayala L, Goor DA, Ramot B (1986) Platelet size and mass as an indicator for platelet transfusion after cardiopulmonary bypass. Circulation 74(5 Pt 2):153–158Google Scholar
  46. 46.
    Akpinar I, Sayin MR, Gursoy YC, Aktop Z, Karabag T, Kucuk E, Sen N, Aydin M, Kiran S, Buyukuysal MC et al (2014) Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. J Cardiol 63:112–118Google Scholar
  47. 47.
    Akpek M, Kaya MG, Yarlioglues M et al (2011) Relationship between platelet indices and spontaneous echo contrast in patients with mitral stenosis. Eur J Echocardiogr 12:865–870Google Scholar
  48. 48.
    Akpinar I, Sayin MR, Gursoy YC, Karabag T, Kucuk E, Buyukuysal MC, Aydin M, Haznedaroglu IC (2013) Plateletcrit: A platelet marker associated with saphenous vein graft disease. Herz.  https://doi.org/10.1007/s00059-013-3798-y Google Scholar
  49. 49.
    Uğur M, Ayhan E, Bozbay M, Çiçek G, Ergelen M, Işık T, Uyarel H, Ertaş G, Çakıllı Y, Öz A et al (2014) The independent association of plateletcrit with long-term outcomes in patients undergoing primary percutaneous coronary intervention. J Crit Care 29:978–981Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Irfan Veysel Duzen
    • 1
    Email author
  • Elif Oguz
    • 2
  • Yusuf Cekici
    • 3
  • Fethi Yavuz
    • 4
  • Ertan Vuruskan
    • 1
  • Isa Sincer
    • 5
  • Fatih Poyraz
    • 6
  • Hayri Alıcı
    • 7
  • Umit Yuksek
    • 8
  • Abdullah Orhan Demirtas
    • 4
  • Murat Sucu
    • 1
  1. 1.Faculty of Medicine, Department of CardiologyGaziantep UniversityGaziantepTurkey
  2. 2.Faculty of Medicine, Department of PharmacologyMedeniyet UniversityIstanbulTurkey
  3. 3.Department of CardiologySanlıurfa Mehmet Akif Inan Research and Training HospitalSanlıurfaTurkey
  4. 4.Department of CardiologyAdana City Education and Research HospitalAdanaTurkey
  5. 5.Faculty of Medicine, Department of CardiologyAbant Izzet Baysal UniversityBoluTurkey
  6. 6.Department of CardiologyGaziantep Defa Life HospitalGaziantepTurkey
  7. 7.Department of CardiologyGaziantep Hatem HospitalGaziantepTurkey
  8. 8.Faculty of Medicine, Department of CardiologyYakın Dogu UniversityNicosiaCyprus

Personalised recommendations